Vectus Biosystems Ltd
VBS
Company Profile
Business description
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
Contact
26-34 Dunning Avenue
Unit 5, Ground Floor
Rosebery
SydneyNSW2018
AUST: +61 283441300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
Stocks News & Analysis
stocks
Avoid these overvalued ASX shares
The two shares with the highest price to fair value in our Australian coverage.
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
Watching AI monetization, capex’s impact on margins, and guidance on Azure.
stocks
Lithium’s latest drop and what it means for ASX investors
Volatility returns to the lithium market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,995.70 | 5.50 | 0.06% |
| CAC 40 | 8,363.14 | 23.03 | 0.28% |
| DAX 40 | 25,011.35 | 164.66 | 0.66% |
| Dow JONES (US) | 52,224.64 | 385.38 | 0.74% |
| FTSE 100 | 10,585.91 | 61.15 | 0.58% |
| HKSE | 24,950.60 | 181.69 | -0.72% |
| NASDAQ | 25,837.21 | 329.13 | 1.29% |
| Nikkei 225 | 67,436.77 | 1,204.59 | 1.82% |
| NZX 50 Index | 13,691.46 | 35.43 | 0.26% |
| S&P 500 | 7,509.20 | 65.92 | 0.89% |
| S&P/ASX 200 | 8,811.20 | 4.70 | 0.05% |
| SSE Composite Index | 3,877.52 | 13.15 | 0.34% |